If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Application based on results from the TROPION-Breast01 Phase III trial
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Subscribe To Our Newsletter & Stay Updated
